$TOVX Cashflow Statement | Understand Stock

$TOVX

$0.19 -$0.01 (2.79%) Close

$TOVX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Subsidiary stock issuances to vendor
Income tax benefit
In-process research and development impairment
Goodwill impairment
Change in fair value of contingent consideration
Right of use asset
Payment of contingent consideration
Loss on asset disposal
Non - cash lease expense
Depreciation
Deferred research and development tax credit
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Deposits and other assets
Accounts payable
Accrued expenses
Accrued employee benefits
Lease liability
Operating lease liability

Net Cash Used In Operating Activities
Cash Flows From Investing Activities:
Purchases of property and equipment
Cash paid for business combination; net of cash acquired
Pre-acquisition loan to VCN
Net Cash Used In Investing Activities
Cash Flows From Financing Activities:
Payment of loans payable
Proceeds from issuance under at - the - market offering, net of issuance cost
Purchase of treasury stock
Proceeds from "at-the-market" stock issuance
Payment of contingent consideration
Proceeds from issuance Common Stock and Warrants offering, net of issuance costs
Proceeds from warrant inducement
Proceeds from long term debt
Proceeds from issuance of common stock for warrant exercises
Tax credit receivable
Net Cash Provided By Financing Activities

Net increase (decrease) in cash and cash equivalents
Effects of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted at the beginning of this period
Cash and cash equivalents and restricted cash at the end of this period
Supplemental non-cash investing and financing activities:
Conversion of preferred stock
Series A Preferred Stock
Series B Preferred Stock
Series C convertible preferred stock
Series D convertible preferred stock

Effect of Series A Preferred Stock price adjustment
Series A Preferred Stock
Total effect of Series A Preferred Stock price adjustment
Return of SYN Biomics Stock
Deemed dividends for accretion of Series B Preferred Stock discount
Right of use assets obtained in exchange for lease liabilities
In-kind dividends in preferred stock
Fair value of contingent consideration issued in a business combination
Fair value of equity issued as consideration in a business combination
Effective settlement of pre-closing VCN financing
Goodwill measurement period adjustment
In-process R&D measurement period adjustment
Deferred tax liability measurement period adjustment
Effect of Warrant exercise price adjustment

NONCASH FINANCING ACTIVITIES:
Noncash equity issuance costs and deemed dividend
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet
Cash and cash equivalents
Restricted cash included in other long-term assets

Comments